Skip to main content

Advertisement

SpringerLink
Log in

Effect of hepatitis B and C clearance on atazanavir exposure

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Wang XZ, Li D, Tao QM, Lin N, Chen ZX (2006) A novel hepatitis B virus X-interactive protein: cytochrome C oxidase III. J Gastroenterol Hepatol 21:711–715

    Article  CAS  PubMed  Google Scholar 

  2. Niu Y, Wu Z, Shen Q, Song J, Luo Q, You H, et al (2013) Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig Liver Dis 45:1041–1048

    Article  CAS  PubMed  Google Scholar 

  3. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA (1996) Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 24:458–467

    Article  CAS  PubMed  Google Scholar 

  4. Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF (2013) Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol 69:1777–1784

    Article  CAS  PubMed  Google Scholar 

  5. Gervasoni C, Meraviglia P, Minisci D, Ferraris L, Riva A, Landonio S, et al (2015) Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? PLoS One 10:e0123670

    Article  PubMed Central  PubMed  Google Scholar 

  6. Pageaux GP, le Bricquir Y, Berthou F, Bressot N, Picot MC, Blanc F, Michel H, Larrey D (1998) Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 10(6):491–495

    Article  CAS  PubMed  Google Scholar 

  7. Kiang TK, Wilby KJ, Ensom MH (2013) Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet 52:487–510

    Article  CAS  PubMed  Google Scholar 

  8. Milazzo L, Cattaneo D, Calvi E, Gervasoni C, Mazzali C, Ronzi P, et al (2015) Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. Int J Antimicrob Agents 45:545–549

    Article  CAS  PubMed  Google Scholar 

  9. Bentué-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E (2009) Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 5:1455–1468

    Article  PubMed  Google Scholar 

  10. de Lastours V, Ferrari Rafael De Silva E, Daudon M, Porcher R, Loze B, Sauvageon H, et al (2013) High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 68:1850–1856

    Article  PubMed  Google Scholar 

  11. Van den Eynde E, Ferrer E, Podzamczer D (2014) Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir. AIDS 28:1538–1539

    Article  PubMed  Google Scholar 

Download references

Transparency declarations

None to declare.

Funding

This study was carried out as part of our routine work.

Conflict of interest

The authors declare that they have no competing interests.

Compliance with ethical standards

This is a retrospective observation describing a case; the patient provided written consent for the case report.

Author information

Authors and Affiliations

  1. 3rd Division of Infectious Diseases, L. Sacco University Hospital, Via GB Grassi 74, 20157, Milan, Italy

    Cristina Gervasoni & Laura Milazzo

  2. Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy

    Dario Cattaneo

  3. Clinical Microbiology Virology and Diagnosis of Bioemergency, L Sacco University Hospital, Milan, Italy

    Valeria Micheli

  4. Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy

    Valentina Di Cristo

Authors
  1. Cristina Gervasoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dario Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valeria Micheli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valentina Di Cristo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Milazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Gervasoni.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gervasoni, C., Cattaneo, D., Micheli, V. et al. Effect of hepatitis B and C clearance on atazanavir exposure. Eur J Clin Pharmacol 71, 1409–1411 (2015). https://doi.org/10.1007/s00228-015-1926-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1926-8

Keywords

Search

Navigation